The Hearst Health Prize: The First Five Years

The Hearst Health Prize is the first national annual award for excellence in population health. The prize was established to discover, support, and showcase the work of an individual, group, organization, or institution that has successfully implemented a population health program or intervention that has made a measurable difference in health outcomes. Now, 5 years since the award\u27s inception, this article reflects on how submissions for the prize collectively mirror - and may even predict - changes within the field of population health. It examines how the most successful programs demonstrated genuine, measurable improvements in health outcomes and/or health behaviors. In exploring the work of these outstanding programs, the aim of this article is to help disseminate best practices, advance the mission of the prize, and inspire improvements in population health practices

Treatment of primary breast cancer with chemotherapy and tamoxifen.

We studied the possibility that the addition of tamoxifen to L-phenylalanine mustard combined with 5-fluorouracil enhances the benefit from the latter two drugs that has been observed in women with primary breast cancer and positive axillary nodes. Recurrence of disease was reduced at two years in patients given the three-drug regimen whose tumor estrogen-receptor levels were greater than or equal to 10 fmol. Among patients greater than or equal to 50 years old treatment failure was significantly reduced (P less than 0.001): by 51 per cent in those with one to three positive nodes and by 64 per cent in those with four or more. Higher receptor levels were associated with a greater probability of disease-free survival. Patients less than or equal to 49 years old were less responsive: those with one to three positive nodes received no benefit from tamoxifen at any receptor level, whereas those with four or more appeared to have reduced treatment failure associated with higher receptor levels. This adjuvant chemotherapy is not indicated in patients less than or equal to 49 years old whose tumor receptor levels are below 10 fmol; there is a suggestion of benefit in patients greater than or equal to 50 years old whose levels are low

Making Human Rights Emotional: A Research Agenda to Recover Shame in "Naming and Shaming"

WOS: 000481613700001Shame is an emotion that is the cornerstone of International Relations (IR) human rights scholarship but remains undertheorized from an explicitly emotional perspective. Given the dubious and unsettled efficacy of human rights "naming and shaming" campaigns, in this article, we outline the theoretical and methodological contours of a research agenda designed (1) to uncover the emotional content of naming and shaming and (2) to pay greater attention to how nonstate actors, especially human rights nongovernmental organizations (NGOs), evoke and experience shame, thus engaging in "emotional diplomacy." Drawing on theories of emotions in IR and political psychology, we present a thicker account of shame by highlighting the individual and social origins of shame, discussing different varieties of shame, and by distinguishing between emotions that are often conflated with shame. We end with a discussion of the methodological tools suitable for pursuing this agenda, using examples of prominent human rights NGOs